Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP increased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 85.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,300 shares of the company's stock after purchasing an additional 2,900 shares during the quarter. Two Sigma Advisers LP's holdings in Axsome Therapeutics were worth $533,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AXSM. BVF Inc. IL grew its position in Axsome Therapeutics by 32.7% in the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after acquiring an additional 342,064 shares in the last quarter. Geode Capital Management LLC grew its position in Axsome Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock valued at $77,228,000 after acquiring an additional 4,079 shares in the last quarter. Invesco Ltd. grew its position in Axsome Therapeutics by 10.8% in the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company's stock valued at $58,589,000 after acquiring an additional 67,285 shares in the last quarter. Hood River Capital Management LLC grew its position in Axsome Therapeutics by 3.2% in the 4th quarter. Hood River Capital Management LLC now owns 644,785 shares of the company's stock valued at $54,555,000 after acquiring an additional 19,701 shares in the last quarter. Finally, Lazard Asset Management LLC grew its position in Axsome Therapeutics by 525.7% in the 4th quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after acquiring an additional 451,737 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Up 2.3%

AXSM stock traded up $2.52 during trading on Thursday, hitting $110.66. 684,558 shares of the company's stock were exchanged, compared to its average volume of 688,451. The business has a 50-day moving average price of $106.05 and a two-hundred day moving average price of $106.35. The stock has a market capitalization of $5.45 billion, a price-to-earnings ratio of -18.47 and a beta of 0.46. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22.

Insider Buying and Selling

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $103.45, for a total value of $2,069,000.00. Following the completion of the sale, the chief operating officer now owns 5,783 shares in the company, valued at approximately $598,251.35. The trade was a 77.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark Coleman sold 3,750 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total value of $395,512.50. Following the completion of the sale, the director now owns 50,387 shares of the company's stock, valued at approximately $5,314,316.89. This represents a 6.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,423 shares of company stock worth $4,950,619 over the last 90 days. 22.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on AXSM shares. Mizuho lifted their target price on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research report on Thursday, March 27th. Cantor Fitzgerald raised Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. Jefferies Financial Group initiated coverage on Axsome Therapeutics in a research report on Monday, April 7th. They set a "buy" rating and a $200.00 price objective for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Axsome Therapeutics has an average rating of "Buy" and a consensus price target of $173.00.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.